SignPath Pharma (www.signpathpharma.com) is a clinical stage biotechnology company (Delaware C Corp.) founded in 2006. Currently, SignPath is actively developing products to treat cancer and mitigate drug-induced cardiac arrhythmia, which is a serious and common side effect of many drugs, and heart muscle damage caused by chemotherapy.